Aosaikang Licenses Adlai Nortye's Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
CompanyDeals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
CompanyDrug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
CompanyDeals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
CompanyDeals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
CompanyDrug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
CompanyDeals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Broncus Medical Acquires Valgen Stake from Venus for $15 Million
CompanyDeals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
CompanyDrug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Hengrui's HRS-6257 Receives IND Approval for Novel Pain Therapy in China
CompanyDrug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
CompanyDrug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO as Surgical Robotics Leader
CompanyDeals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

J&J's JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
CompanyDrug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial